TY - JOUR
T1 - Effect of insulin-like growth factor i in murine muscular dystrophy
AU - Zdanowicz, Martin M.
AU - Moyse, Jeffrey
AU - Wingertzahn, Mark A.
AU - O’connor, Margaret
AU - Teichberg, Saul
AU - Slonim, Alfred E.
PY - 1995/11
Y1 - 1995/11
N2 - In muscular dystrophy there is an imbalance between muscle protein synthesis and protein degradation, resulting in net muscle catabolism and progressive muscle weakness and wasting. Both insulin and insulin-like growth factor I (IGF-I) are known to have an anabolic effect on skeletal muscle, which is believed to be enhanced in the presence of elevated concentrations of amino acids. We examined the effects of 4-week administration of recombinant human IGF-I (rhIGF-I), both alone and supplemented with a high protein diet (HPD), on muscle metabolism, morphology, and function in the 129 ReJ dystrophic mouse. rhIGF-I significantly reduced muscle protein degradation (P < 0.001), increased muscle protein content (P < 0.05), decreased fiber area variability (P < 0.01), and increased hind limb utilization (P < 0.01). Supplementation of rhIGF-I therapy with a HPD resulted in a significant increase in muscle protein synthesis (P < 0.05) in addition to a further increase in the above parameters. We conclude that rhIGF-I causes an improvement in muscle metabolism, morphology, and function in dystrophic mice, and this effect is further enhanced by the presence of a HPD.
AB - In muscular dystrophy there is an imbalance between muscle protein synthesis and protein degradation, resulting in net muscle catabolism and progressive muscle weakness and wasting. Both insulin and insulin-like growth factor I (IGF-I) are known to have an anabolic effect on skeletal muscle, which is believed to be enhanced in the presence of elevated concentrations of amino acids. We examined the effects of 4-week administration of recombinant human IGF-I (rhIGF-I), both alone and supplemented with a high protein diet (HPD), on muscle metabolism, morphology, and function in the 129 ReJ dystrophic mouse. rhIGF-I significantly reduced muscle protein degradation (P < 0.001), increased muscle protein content (P < 0.05), decreased fiber area variability (P < 0.01), and increased hind limb utilization (P < 0.01). Supplementation of rhIGF-I therapy with a HPD resulted in a significant increase in muscle protein synthesis (P < 0.05) in addition to a further increase in the above parameters. We conclude that rhIGF-I causes an improvement in muscle metabolism, morphology, and function in dystrophic mice, and this effect is further enhanced by the presence of a HPD.
UR - http://www.scopus.com/inward/record.url?scp=0028835269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028835269&partnerID=8YFLogxK
U2 - 10.1210/endo.136.11.7588220
DO - 10.1210/endo.136.11.7588220
M3 - Article
C2 - 7588220
AN - SCOPUS:0028835269
VL - 136
SP - 4880
EP - 4886
JO - Endocrinology
JF - Endocrinology
SN - 0013-7227
IS - 11
ER -